Xenova's US deal heads new biotech boom
Tuesday 28 January 1997
With another, BioFocus, waiting in the wings to launch on Ofex, the growing queue of fledgling companies ready to come to market suggests the sector has overcome last year's problems when several companies either pulled or delayed their floats.
Xenova said the deal with Bristol-Myers involved screening its "library" of more than 25,000 microbes and 6,000 plant extracts against disease processes thrown up by the US group's genetic research. The aim will be to isolate a molecule or molecules which can inhibit the target process, thereby checking the disease.
Xenova will also supply its expertise in so-called "infomatics", which involves using a database to identify the chemical which results from the screening process or determine whether it is a new one in order to aid its reproduction in the laboratory.
As well as providing the drug target technology, Bristol-Myers will undertake the development and marketing of any product which emerges from the collaboration. Xenova will do the screening, identify any chemicals which result and supply the chemical to Bristol-Myers, which will cover research costs and make undisclosed milestone and royalty payments.
Xenova's technology is based on the discovery of drugs derived from naturally occurring micro-organisms, such as those found in fungi and bacteria, and from plants and plant extracts. Its most advanced drug candidate under development is an anti-cancer treatment which is still three years away from the market. But Louis Nisbet, chief executive, pointed out that Taxol, one of Bristol-Myers' main anti-cancer drugs, was originally derived from a plant.
Separately, Cambridge Antibody Technology said it planned to seek a full listing in March at a price which analysts expect will value the company at between pounds 85m and pounds 95m. It is thought to be looking to raise pounds 30m in an institutional placing, having pulled in pounds 16.6m from investors since the company was founded in 1990.
The Bioscience Innovation Centre, which is raising pounds 6m in its placing and offer, is also based in Cambridge. It aims to offer start-up biotech groups the infrastructure to run their business, including providing laboratories and management skills.
- 2 Harry Potter fans can apply to the Hogwarts-inspired College of Wizardry
- 3 Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
- 4 Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
- 5 Orange Wednesdays are no more
Weather bomb in pictures: Storms cuts power for tens of thousands – and snow is on the way
Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
Russell Brand was rendered speechless on Question Time by this man
Fury at Airbus after it hints the super-jumbo may be mothballed
Disgruntled RBS worker writes hilarious open letter to Russell Brand after anti-capitalist publicity stunt leaves him hungry
Nigel Farage defends Kerry Smith 'ch***y' comment: 'If you are going for a Chinese, what do you say you’re going for?'
Nigel Farage's approval rating hits 'record low' as popularity suffers in wake of Ukip sex scandal
Pakistan school attack live: Taliban kill at least 132 children in 'horrifying' massacre
Sony hack: Angelina Jolie branded 'seriously out of her mind' in further embarrassing leaked email saga
Panic Saturday: 13 million Britons spend £1.2bn – while 13 million others across the country live in poverty unable to afford food
iJobs Money & Business
£20000 - £25000 per annum + OTE £40,000 + Car + Pension: SThree: SThree are a ...
£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...
£20000 - £25000 per annum + OTE £35000: SThree: SThree are a global FTSE 250 b...
£20000 - £25000 per annum + OTE £35K - £45K: SThree: SThree Group have been we...